度鲁特韦钠盐
| CAS号 | 1051375-19-9 | 货号 | BCP11890 |
| 中文名 | 度鲁特韦钠盐 | ||
| 英文名 | Dolutegravir sodium | ||
| 中文别名 | 度鲁特韦钠; | ||
| 英文别名 | Dolutegravir sodium salt;S/GSK1349572 sodium;GSK 1349572A;GSK-1349572A;GSK1349572A; | ||
| 分子式 | C20H18F2N3NaO5 | 分子量 | 441.36 |
| 生物活性 | Dolutegravir (DTG, GSK1349572) is metabolized primarily by uridine diphosphate glucuronyltransferase (UGT)1A1, with a minor role of cytochrome P450 (CYP)3A, and with renal elimination of unchanged drug being extremely low (< 1% of the dose). Fifty-three percent of the total oral dose is excreted unchanged in the feces but it is unknown if all or part of this is due to unabsorbed drug or some percentage of biliary excretion of the glucuronide conjugate which can be further degraded to form the parent compound in the gut lumen. The current Food and Drug Administration (FDA) draft guidance for renal impairment studies states that a pharmacokinetic (PK) study in patients with renal impairment should be conducted even for those drugs primarily metabolized or secreted in bile, because renal impairment can inhibit some pathways of hepatic and gut drug metabolism and transport. | ||
| 信号通路 | Protease/Metabolic Enzyme Microbiology/Virology | ||
| 靶 点 | Integrase HIV | ||
结构式
本页面部分数据来自于公开的网络资源,所以瀚香生物不能保证其准确性。
不同批次的产品详情请咨询我们的客服：
- 全国免费电话：400-099-8200
- 在线客服:
瀚香生物（Biochempartner) 的所有产品和服务仅用于科学研究，禁止用于人体和治疗！